Senate Drug Pricing Bill: Even Worse Than The House Version
US Senate’s updated version of drug pricing legislation is even worse for industry when it comes to the proposed price ‘negotiation’ authority, a Congressional Budget Office analysis indicates. The big numbers facing the industry just keep getting bigger.
You may also be interested in...
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.
The US pharmaceutical industry is finally on the right side of the inflation debate, with drug price increases clearly lagging well behind overall consumer price growth. It is, however, probably too late to make a difference in the prospects of price control legislation.
Interecept is reviving hopes that it will be able to capture a potential blockbuster indication for its liver disease drug Ocaliva. The development strategy might never happen again if the US drug pricing bill becomes law.